Companies Dominating the Essential Thrombocythemia Landscape
- Active Biotech AB
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Incyte
- Bayer AG
- USV Private Limited.
- Merck & Co., Inc.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- AstraZeneca
- Takeda Pharmaceutical Company Limited
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Currently in 2025, the industry revenue of essential thrombocythemia is evaluated at USD 960.28 million.
The global essential thrombocythemia market is poised to increase from USD 921.57 million in 2024 to USD 1.97 billion by 2037, registering a CAGR of more than 6% during the forecast period, from 2025 through 2037.
North America industry is likely to account for largest revenue share of 35% by 2037, driven by rising count of people living with ET in the region.
The major players in the market include Active Biotech AB, Incyte, Bayer AG, USV Private Limited., Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca, Takeda Pharmaceutical Company Limited.
